Lipocine Inc. 8-K

What Happened
Lipocine Inc. (LPCN) filed a Form 8-K with the SEC on January 12, 2026 (Accession No. 0001493152-26-001864) reporting an "Other Event" under Item 8.01. The filing attaches a corporate presentation as Exhibit 99.1 and includes the Inline XBRL cover page (Exhibit 104). The filing does not report earnings, revenue figures, executive changes, or new material agreements.

Key Details

• Filing date: January 12, 2026; Form 8-K, Item 8.01 (Other Events).
• Exhibit 99.1: Corporate Presentation is attached to the filing.
• Exhibit 104: Cover Page Interactive Data File (Inline XBRL) is included.
• No financial statements, earnings results, or management changes were reported in this 8-K.

Why It Matters
This 8-K is an informational update that makes Lipocine’s latest corporate presentation available to investors and the public. While it does not disclose financial results or material corporate actions, the presentation may contain strategy, program or pipeline updates—so investors should review Exhibit 99.1 on the SEC EDGAR site or the company’s investor page for any relevant business or clinical information.